4D Molecular Therapeutics, Inc. (FDMT)

NASDAQ: FDMT · Real-Time Price · USD

10.70

-0.49 (-4.38%)

At close: Dec 5, 2025, 4:00 PM EST

10.91

+0.21 (1.96%)

After-hours: Dec 5, 2025, 7:24 PM EST

4D Molecular Therapeutics Employees

4D Molecular Therapeutics had 227 employees as of December 31, 2024. The number of employees increased by 80 or 54.42% compared to the previous year.

Employees

227

Change (1Y)

80

Growth (1Y)

54.42%

Revenue / Employee

$529

Profits / Employee

-$921,485

Market Cap

611.35M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	227	80	54.42%
Dec 31, 2023	147	7	5.00%
Dec 31, 2022	140	16	12.90%
Dec 31, 2021	124	41	49.40%
Dec 31, 2020	83	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	92,900
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000

Employee Rankings

FDMT News

14 days ago - 4D Molecular Therapeutics, Inc. (FDMT) Presents at Jefferies London Healthcare Conference 2025 Transcript - Seeking Alpha
16 days ago - 4DMT to Participate in 8th Annual Evercore Healthcare Conference - GlobeNewsWire
19 days ago - 4DMT Appoints Kristian Humer as Chief Financial Officer - GlobeNewsWire
21 days ago - 4DMT Announces New Employment Inducement Grants - GlobeNewsWire
26 days ago - 4DMT Reports Third Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones - GlobeNewsWire
4 weeks ago - 4DMT to Participate in Jefferies 2025 London Healthcare Conference - GlobeNewsWire
4 weeks ago - 4DMT Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
4 weeks ago - 4DMT Announces Positive Long-Term Data from Phase 1/2 PRISM Clinical Trial in Wet AMD Supporting 4D-150's Potential as a Backbone Therapy with Consistent and Durable Benefit over Multiple Years - GlobeNewsWire